Avalo Therapeutics Appoints Jennifer Riley As Chief Strategy Officer, Stock Down

(RTTNews) - Avalo Therapeutics, Inc. (AVTX), the clinical-stage biotechnology company announced the appointment of Jennifer Riley as chief strategy officer with effect from January 1. Shares are down 1.75 percent in the pre-market.

Riley will be responsible for managing corporate strategy and planning the commercial and product pipeline, aiming to boost growth and innovation in the company. She has over 20 years of experience in the biotechnology and pharmaceutical industries.

Thursday, AVTX had closed 4.74% less at $7.43 on the Nasdaq. In the pre-market trading, AVTX is 1.75% high at $7.30.